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Nicotinamide Phosphoribosyltransferase: A Potent
Therapeutic Target in Non-small Cell Lung Cancer with
Epidermal Growth Factor Receptor-Gene Mutation
Shunsuke Okumura, MD, PhD, Takaaki Sasaki, MD, PhD, Yoshinori Minami, MD,
and Yoshinobu Ohsaki, MD, PhD
Background: Non-small cell lung cancer (NSCLC) often has an
epidermal growth factor receptor (EGFR) gene mutation. Growth of
EGFR-gene-mutated NSCLC depends predominantly on EGFR sig-
naling and requires a large amount of intracellular ATP to activate
EGFR signal transduction. Nicotinamide phosphoribosyltransferase
(NAMPT) is a rate-limiting enzyme in nicotinamide adenine dinu-
cleotide biosynthesis, and it regulates intracellular ATP levels in
mammalian cells. The effect of NAMPT inhibition on NSCLC has
not been completely understood.
Methods: We aimed to clarify the hypothesis that NAMPT inhibi-
tion suppresses growth of EGFR-gene-mutated NSCLC through
reduction of intracellular ATP levels, using NAMPT-siRNA transfec-
tion and NAMPT inhibitor FK866. We used four lung adenocarcinoma
cell lines, including H358 (Wild type EGFR), LC2 (EGFRL858R), PC9
(EGFRDel E746-A750), and H1975 (EGFRL858RT790M), and evaluated
the effect of FK866 on these cells and its mechanisms, using cell
proliferation, Western blot, ATP, and apoptosis assay.
Results: We found that (1) H358, LC2, and H1975 cell lines highly
expressed NAMPT-mRNA; (2) NAMPT-specific siRNA and FK866
suppressed proliferation of these NSCLCs; (3) FK866 reduced
intracellular ATP levels in H1975 cells; (4) FK866 dephosphory-
lated EGFR signal proteins, including EGFR, Akt, Map kinase
kinase 1/2, and extracellular signal-regulated kinase 1/2 (ERK 1/2);
(5) FK866 induced apoptosis of H1975 cells; and (6) FK866 sup-
pressed growth of H1975 xenograft tumors and attenuated expres-
sion of phospho-ERK 1/2 in the tumors in a tumor-bearing mouse
model.
Conclusion: These findings indicate that NAMPT is a potent ther-
apeutic target in the treatment of EGFR-gene-mutated NSCLC.
Key Words: Non-small cell lung cancer, EGFR, NAMPT, FK866,
ATP.
(J Thorac Oncol. 2012;7: 49–56)
Lung cancer is a leading cause of cancer death worldwide.Among lung cancer pathological types, non-small cell
lung cancer (NSCLC) accounts for up to 80% of lung can-
cers.1 About 60 to 70% of NSCLCs have an overexpression
of epidermal growth factor receptor (EGFR) protein, which is
a member of the receptor tyrosine kinase (RTK) ErbB fam-
ily.2,3 RTKs require intracellular adenosine triphosphate
(ATP) to enhance their kinase activities and transduce their
signals to the downstream pathways. NSCLCs often depend
on the EGFR pathway to maintain survival and growth,
which has been described as an oncogene addiction.4 There-
fore, this coordination of intracellular ATP and EGFR may be
one of the molecular targets in the treatment of EGFR-
addicted NSCLC.
A therapeutic strategy targeting intracellular ATP bind-
ing to the EGFR has been successful in NSCLC treatment.
Gefitinib, an EGFR tyrosine kinase inhibitor (EGFR-TKI),
competitively inhibits intracellular ATP binding to EGFR.
Gefitinib has high antitumor activities against NSCLC with
somatic mutations within the kinase domain of EGFR.5 These
mutant NSCLCs are thought to be addicted to EGFR path-
ways.6 Gefitinib dramatically prolongs progression-free sur-
vival in patients with advanced NSCLC with EGFR muta-
tions.7–9 Nevertheless, NSCLC treated with EGFR-TKIs
often acquire resistance. Most resistance is caused by the
T790M mutation, which is a point mutation of exon 20 in the
EGFR gene (EGFRT790M).10,11
Nicotinamide phosphoribosyltransferase (NAMPT,
also known as visfatin or pre-B-cell colony enhancing factor)
is an enzyme that predominantly catalyzes nicotinamide ad-
enine dinucleotide (NAD).12 NAD serves as a substrate for
enzymes including poly (ADP-ribose) polymerase-1 and sir-
tuin, which is associated with apoptosis resistance and sur-
vival. Therefore, NAMPT is involved in cell growth and
survival.12–17 NAMPT also contributes to energy production
through regulation of NAD and regulates intracellular ATP
levels in mammalian cells.16,18 NAMPT proteins or mRNA
are highly expressed in malignant tumors including glioblas-
toma, colorectal, prostate, ovarian, and lung cancers,19–24 and
NAMPT inhibitors suppress tumor growth.14,25,26 For in-
stance, a NAMPT inhibitor, FK866 induces delayed apopto-
sis of human liver carcinoma cells.26 NAMPT is essential for
the energetic systems in mammalian cells including cancer
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cell. Wang et al.21 reported that NAMPT expression was
up-regulated in NSCLC. Therefore, we speculated that
NAMPT expression would be highly increased in EGFR-
addicted NSCLC, especially H1975 cells that require a large
amount of ATPs, and NAMPT may be a potential therapeutic
target in EGFR-addicted NSCLC. Nevertheless, the potential
mode of action of the NAMPT inhibitor remains equivocal,
and little is known about the efficacy of NAMPT inhibitors
in NSCLC. We hypothesized that NAMPT will be associ-
ated with growth of EGFR-addicted NSCLC including
EGFRT790M-mutated lung cancer and that attenuation of
NAMPT in NSCLC will result in tumor regression by means
of reduction of intracellular ATP levels. In this study, we
showed the tumoricidal effect of FK866, a NAMPT inhibitor,
on NSCLC, including gefitinib-resistant NSCLC, and a po-
tential mechanism of the antitumor activity of FK866 in
EGFR-gene-mutated NSCLC.
MATERIALS AND METHODS
Additional detailed protocols are described in Supple-
mentary Methods (http://links.lww.com/JTO/A180).
Cell Culture and Reagents
Four lung adenocarcinoma cell lines and one lung
fibroblast cell line were used: H358 cells have the wild-type
EGFR gene; LC2 cells contain an L858R exon 21 point
mutation in EGFR; PC9 cells have an exon 19 deletion in
EGFR; H1975 cells have L858R and T790M, an exon 20
point mutation in EGFR; and WI38 is a lung fibroblast cell
line. H358, LC2, and PC9 cells are sensitive to gefitinib but
H1975 cells are not. These cell lines were purchased from the
America Type Culture Collection (Manassas, VA) except the
PC9 cell line, which was a kind gift from Professor Kazuto
Nishio, Department of Genome Biology, Kinki University.
Cells were maintained in RPMI with 10% fetal bovine serum,
L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin
(100 mg/ml). All media were gassed with a humidified
mixture of 95% air and 5% CO2 (normoxic condition).
Gefitinib was purchased from AstraZeneca (Maccles-
field, UK) and FK866 was obtained from Axon Medchem
(Groningen, The Netherlands). The agents were prepared
as 10 mM stock solutions in dimethyl sulfoxide (DMSO).
These stock solutions were stored at 4°C until use. Stealth
Select RNAi duplexes, OPTI-MEM I reduced-serum me-
dium, Lipofectamine RNAiMAX, and BLOCK-iT Alexa
Fluor Red Fluorescent Oligo were obtained from Invitro-
gen (Carlsbad, CA).
EGFR, phospho-EGFR (Tyr1068), Akt, phospho-Akt
(Ser473), extracellular signal-regulated kinase 1/2 (ERK1/2),
phospho-ERK1/2 (Tyr202/Tyr204), MAP kinase kinase 1/2
(MEK1/2), phospho-MEK1/2 (Ser217/221), antibodies, -ac-
tin, horseradish peroxidase (HRP)-labeled antimouse IgG,
and HRP-conjugated antirabbit IgG antibody were from Cell
Signaling Technology (Tokyo, Japan); rhodamine-conjugated
antirabbit IgG antibody was purchased from Abcam (Cam-
bridge, UK). Rabbit anti-NAMPT antibody was obtained
from Bethyl Laboratories (Montgomery, TX).
Quantitative Real-Time RT-PCR
NAMPT-mRNA in cells was measured by quantitative
reverse-transcription polymerase chain reaction (RT-PCR).
Gene expression was normalized to the endogenous house-
keeping gene, GAPDH. Lung cancer cells were incubated in
complete medium for 3 days. Supernatants were removed,
and cells were washed twice with phosphate-buffered saline
(PBS). Total cellular RNA was extracted from culture cells
by a FastPure RNA kit (Takara Bio, Shiga, Japan). Primer
sets were obtained from Takara Bio. The sequences of primer
sets for quantitative RT-PCR are provided in Supplemental
Table S1 (http://links.lww.com/JTO/A183). A LightCycler
RNA Amplification Kit SYBR Green I (Roche, Mannheim,
Germany) was used, and real-time PCR was performed using
a LightCycler 2.0 (Roche). The relative quantification was
determined using delta-Ct value by LightCycler Software 4.0
(Roche).
Small Interfering RNA Transfection
The detailed protocol is described in Supplementary
Methods. The sequences of the specific siRNAs are described
in Supplemental Table S2 (http://links.lww.com/JTO/A184).
Cell Proliferation Assay
Lung cancer cells or lung fibroblast cells (3.0–10.0 
103 cells) were cultured in 96-well plates in complete me-
dium (RPMI with 10% fetal bovine serum, L-glutamine, and
penicillin/streptomycin) and incubated in humidified atmo-
sphere under normoxic conditions overnight. The next day,
the complete medium was removed from the wells and
replaced by new complete medium containing the indicated
agent (gefitinib, FK866, or DMSO). Cells were treated with
such agents for 3 days, and cell proliferation was evaluated using
a 5-bromo-2-deoxy-uridine (BrdU) cell proliferation assay kit
(Roche, Switzerland) and determined by a microplate luminom-
eter (Thermo Scientific, Yokohama City, Japan).
Clonogenic Growth Assay
The detailed protocol is shown in Supplemental
Methods.
ATP Assay
Intracellular ATP levels were evaluated by an ATP
bioluminescence assay kit (Roche) as described.27,28 Under
normoxic conditions, 5  103 H1975 cells were incubated in
96-well plates with or without FK866 for the indicated
periods. Subsequently, cells in each well were counted by the
trypan blue exclusion method, and these cells were collected
in the cell-lysis solution. In this assay, the light emission
caused by interaction between ATP and luciferin was mea-
sured by a chemiluminometer (LAS-3000; Fujifilm, Tokyo,
Japan). ATP concentrations in the solution were determined
by comparison with a standard ATP solution. From the
results of ATP assays, intracellular ATP levels were calcu-
lated by the number and volume of cells in the solution.
Western Blotting
LC2, H1975, and PC9 cells (5.0–10  105 cells) were
incubated in complete medium. The next day, the complete
medium was changed to new complete medium containing
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DMSO, FK866, or gefitinib. NSCLCs were incubated under
normoxic condition for next 3 days. Then, treated cells were
twice washed with PBS, and collected in Cell Lysis Buffer
(CST, Tokyo, Japan) containing PhosSTOP Phosphatase In-
hibitor Cocktail (Roche, Mannheim, Germany) and Complete
Protease Inhibitor Cocktail (Roche). Protein was extracted
from the cells, and SDS-PAGE analysis was performed
according to the manufacturer’s instructions. We used anti-
bodies at a 1:1000 dilution, except for the anti-NAMPT
antibody at a 1:5000 dilution. HRP-labeled secondary anti-
bodies and an ECL Western blotting (WB) system (GE
Healthcare, Chalfont, UK) were used. The expression of
proteins was measured using an LAS-3000 imaging system
(Fujifilm) and quantitatively measured by MultiGauge
Ver.2.2 (Fujifilm).
Apoptosis Detection
Apoptotic cells were evaluated by flow cytometry. An
annexin V-FITC apoptosis detection kit (BD Bioscience, San
Jose, CA) was used. First, 3  105 H1975 cells were
incubated in complete medium for 24 hours. Next, their
supernatants were removed, and the cells were incubated in
new complete medium with or without agents including
FK866 (50 nM) or gefitinib (10 M) for 72 hours. Cells were
washed twice with 4°C PBS and suspended in the buffer at a
concentration of 1.0  106 cells. These cells were labeled
with annexin V-FITC or propidium iodide (PI; BD Biosci-
ence). In each treated group, a total of 10,000 cells labeled
with FITC or PI were counted using a BD FACSAria II
cytometer (BD Bioscience), and values were analyzed using
BD FACSDiva software ver. 6.1 (BD Bioscience).
Animal Experiments
For a mouse model, 7- to 10-week-old (20–25 g)
female CD-1Foxn1nu/nu mice, which are immunodeficient
strain lacking a thymus, were obtained from Charles River
(Wilmington, MA). Mice were anesthetized with diethyl
ether and then 2.0  106 tumor cells were implanted in the
bilateral flanks. After implantation, mice were treated with
gefitinib (by oral administration once daily) or FK866 (by
intraperitoneal injection twice daily), and the tumor volumes
were measured. Tumor volumes were calculated by the fol-
lowing formula: tumor volume (mm3)  L  W2  1/2 (L:
length, W: width). After 13 days of treatment, mice were
euthanized by exsanguination, and the xenograft tumors were
fixed with 2% paraformaldehyde. Then, xenograft tumors
were embedded in Optimum Cutting Temperature compound
(Sakura Finetek Japan, Tokyo, Japan) and stored at 80°C
until use.
Immunohistochemistry
Frozen tissues were cut into 10 m sections on a
cryostat. Tissue sections were washed with PBS and heated in
a microwave oven for 15 minutes for antigen retrieval. Tissue
sections were washed with PBS-3% Triton X. Then, 1%
BSA-PBS was put on the sections for 1 hour, and tissue
samples were stained with phosphorylated-ERK 1/2 (phos-
pho-ERK1/2) primary antibody overnight at 4°C. Then, sam-
ples were stained with a rhodamine-conjugated secondary
antibody. The expression of phospho-ERK1/2 signal was
visualized by a fluorescence microscopy (Olympus, Tokyo,
Japan).
Statistical Analysis
The measurements are presented as mean  SE. Re-
sults were analyzed by Student t test. Statistical analysis was
performed using Microsoft Excel. Two-sided p values 0.05
were considered to be statistically significant.
RESULTS
Lung Adenocarcinoma Cells Highly Express
NAMPT-mRNA
We measured NAMPT-mRNA expression in four lung
adenocarcinoma cell lines with or without EGFR-gene mu-
tations by quantitative RT-PCR. NAMPT-mRNA expression
in lung cancer cells was compared with that in WI38 cells, a
lung fibroblast cell line.29 Quantitative RT-PCR showed that
the levels of NAMPT-mRNA expression were higher in
lung adenocarcinoma cell lines than in WI38, except for
PC9. The NAMPT-mRNA expression was highest in
H1975 cells (Figure 1A).
NAMPT siRNA Suppresses Cell Proliferation
of NSCLC
Next, we transfected NSCLC cell lines with three
NAMPT-specific siRNA to examine the effects of NAMPT
inhibition on proliferation of NSCLC. The efficacy and effi-
ciency of siRNA knockdowns were monitored by Alexa
Fluor 555-labeled siRNA transfection and WB (Supplemen-
tary Figure S1A and B, http://links.lww.com/JTO/A185). On
the basis of the results, we selected NAMPT siRNA 1 in the
following assay. A BrdU assay showed that NAMPT-specific
siRNA suppressed cell proliferation of all the NSCLCs ex-
cept LC2 compared with a nonspecific siRNA (Figure 1B).
NAMPT Inhibitor FK866 Inhibits Proliferation
of Lung Adenocarcinoma Cells
To determine the efficacy of FK866, the NAMPT
inhibitor, in NSCLC, we used BrdU and clonogenic assays.
On the basis of the results that NSCLC cell proliferation
was suppressed by treatment with NAMPT-specific siRNA
for 48 to 72 hours (Supplementary Figure S1C,
http://links.lww.com/JTO/A185), NSCLCs were subjected to
72 hours of FK866 treatment. The BrdU assay revealed that
FK866 suppressed proliferation of lung cancer cells in a
dose-dependent manner (Figure 2). In comparison to ge-
fitinib, FK866 inhibited proliferation of both gefitinib-sensi-
tive and -resistant cells (Figure 2, Supplementary Figure S2,
http://links.lww.com/JTO/A186). Of note, a high concentra-
tion of FK866 (50 nM) suppressed cell proliferation of H1975
cells, which were resistant to gefitinib, but it only marginally
suppressed proliferation of WI38 (Figure 2).
To confirm the difference between LC2 cells and
H1975 cells in sensitivity to gefitinib and FK866, we
additionally performed a clonogenic assay. The colony
assay revealed that FK866 (10 nM) drastically reduced the
number of H1975 colonies and incompletely reduced LC2
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colonies. (Supplementary Figure S3A and B,
http://links.lww.com/JTO/A187). In contrast, the sensitivity
to gefitinib in H1975 was equivalent to that in LC2 cells.
FK866 Reduces Intracellular ATP Levels in
H1975 Cells
As described above, FK866 suppressed proliferation of
both gefitinib-sensitive and -resistant NSCLC. Next, we stud-
ied the mechanisms of antitumor effect of FK866 on H1975
cells that were resistant to gefitinib. We selected the H1975
cell line to study the inhibitory effect of FK866 and mecha-
nisms as follows because H1975 cells had the highest expres-
sion of NAMPT-mRNA among the four NSCLC cell lines
(Figure 1A), and we considered H1975 cells were better for
the following study. To clarify the mechanism of growth
suppression by FK866, the intracellular ATP concentration
was measured in FK866-treated H1975 cells. ATP levels in
H1975 cells were measured by an ATP bioluminescence
assay and compared with those in the nontreated cells. In the
ATP assay, reduction of intracellular ATP was observed after
24 hours of treatment (Figure 3).
NAMPT Inhibitor Dephosphorylates EGFR
Signal Proteins and Induces Apoptosis in
H1975 Cells
The NAMPT inhibitor suppressed proliferation of
EGFR-addicted NCLC and reduced intracellular ATP levels.
Consequently, we evaluated the alteration of EGFR signaling
in H1975 cells that were treated with FK866 or gefitinib.
SDS-PAGE analysis showed that FK866 (50 nM) suppressed
the expression of phospho-EGFR (Tyr 1068) in the FK866-
treated cells after 72 hours of treatment (Figure 4A). In
contrast to gefitinib (10 M), FK866 dephosphorylated
EGFR, ERK1/2, Akt, and MEK1/2 proteins (Figure 4B, C).
Next, the apoptotic effect of FK866 was evaluated by
flow cytometry to determine the mode of tumoricidal activi-
ties. Flow cytometry showed that FK866 induced cell apo-
ptosis (Figure 5A). In contrast, the induction of apoptosis by
gefitinib was marginal. Both annexin-V FITC and PI signals
increased outstandingly in the FK866-treated cells compared
with those treated with gefitinib (Figure 5B).
FK866 Suppresses Growth of H1975 Xenograft
Tumors in Mice through Suppression of
Phosphorylation of EGFR-Signaling Proteins
Next, we determined the antitumor activity of FK866 in
vivo using a tumor-bearing mouse model. We used CD-
1Foxn1nu/nu nude mice. Mice were treated with the indicated
concentrations of FK866 or gefitinib, and the tumor volume
of H1975 xenografts was measured for 13 days. FK866
prominently inhibited growth of H1975 xenograft tumors in
tumor-bearing mice compared with gefitinib (Figure 6A).
The expressions of phospho-ERK1/2 protein in xeno-
grafts were compared in FK866- and gefitinib-treated mice.
Fluorescent immunohistochemistry revealed that FK866 sig-
nificantly suppressed expression of phospho-ERK1/2 proteins
in xenograft tumors, but gefitinib did not (Figure 6B).
DISCUSSION
Our findings indicate that the NAMPT inhibitor FK866
is efficacious for the treatment of NSCLC with the EGFR
gene mutation. EGFR-gene-mutated NSCLC requires a large
amount of intracellular ATP to maintain survival and pro-
gression of the cancer. NAMPT is a key enzyme in the
intracellular energy pathways in mammalian cells. Therefore,
we selected NAMPT as a possible target to reduce intracel-
lular ATP levels in NSCLC. In this study, we demonstrated
that (1) attenuation of NAMPT function suppressed growth of
EGFR-gene-mutated NSCLCs including those with the
EGFRT790M mutation and that (2) this growth inhibition was
due to dephosphorylation of both EGFR and EGFR-down-
stream proteins through reduction of intracellular ATP levels.
We showed that lung adenocarcinoma cells with or
without EGFR mutation express NAMPT-mRNA (Figure
1A). This result suggested that the growth of these NSCLCs,
at least in part, depends on NAMPT activity. As expected,
addition of NAMPT siRNA and FK866 inhibited cell prolif-
eration in NSCLC with or without EGFR gene mutation
(Figure 1B and 2). Proliferation of these cells was inhibited
by 1-nM to 50-nM FK866, concentrations that correspond to
FIGURE 1. Non-small cell lung cancer (NSCLC) cells over-
express NAMPT-mRNA and NAMPT-specific siRNA sup-
presses proliferation of NSCLC. A, The expression of
NAMPT-mRNA in NSCLCs was measured by real-time re-
verse-transcriptase polymerase chain reaction (RT-PCR).
NAMPT-expression levels were normalized to GAPDH-expres-
sion levels. The mean values were determined from three
independent experiments. B, Cell proliferation was measured
by BrdU assay on day 3 after siRNA transfection. The values
were converted to a ratio in which each value in treated
cells was compared with those in nontreated cells. The
mean values were obtained from four independent
experiments.
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the findings reported by Hasmann and Schemainda.26 PC9
cells were extremely sensitive to FK866. Nevertheless, a
higher concentration of FK866 was required to inhibit pro-
liferation of LC2, H358, and H1975 cells (Figure 2). Watson
et al.22 reported that lung cancer cells with low NAMPT
protein expression were more sensitive to a NAMPT inhibitor
than those with high NAMPT protein expression. We found
that NAMPT-mRNA expression in PC9 cells was slight in
comparison with those of LC2 and H1975 cells, suggesting
that PC9 cells would be more sensitive to FK866 than LC2
and H1975. Addition of FK866 did not remarkably inhibit
proliferation of WI38 lung fibroblast cells, even at high
concentrations (Figure 2). These results suggest that FK866
in high concentrations affect lung cancer cells rather than
normal lung cells, although thrombocytopenia may increase
even at a therapeutic dose, as reported elsewhere.30 Thus,
some modification of FK866 administration, including the
drug delivery system, may be necessary to reduce adverse
effects of the drug in a clinical setting.
H1975 cells were more sensitive to FK866 than LC2
cells, although H1975 cells had 2-fold higher NAMPT-
mRNA expression than LC2 cells (Figure 1A, 2, Supplemen-
FIGURE 3. Intracellular ATP levels decrease in FK866-
treated non-small cell lung cancer (NSCLC). H1975 cells
were treated with 1 nM or 10 nM FK866. ATP biolumines-
cence was assayed to measure ATP levels on the indicated
times. The values are shown as a ratio (treated/nontreated).
FIGURE 2. FK866 suppresses pro-
liferation of non-small cell lung
cancer (NSCLC) cells. Cells were
treated with the indicated concen-
trations of FK866 for 72 hours, and
proliferation was measured by BrdU
assay. The mean values were calcu-
lated from the three independent
experiments.
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FIGURE 4. FK866 suppresses
phosphorylation of EGFR-signal
proteins in non-small cell lung can-
cer (NSCLC). A, H1975 cells were
treated with or without 50 nM
FK866 for the indicated periods.
The expressions of p-EGFR and
-actin proteins at the indicated
hours were assessed by WB. B,
H1975 cells were treated with ge-
fitinib or FK866 for 72 hours. The
expression of EGFR-signal proteins
was evaluated by WB. C, LC2,
H1975, and PC9 cells were treated
with the indicated concentrations
of gefitinib or FK866. MEK1/2 and
p-MEK1/2 expressions were as-
sessed by WB.
FIGURE 5. FK866 induces apopto-
sis of H1975 cells. H1975 cells
were treated with 10 M gefitinib
or 50 nM FK866 for 72 hours. Apo-
ptosis was visualized by FACS. A,
Apoptosis was measured by PI-la-
beled cell counts (right), and the
early phase of apoptosis was mea-
sured by annexin V-FITC signals
(left). B, Numbers of apoptotic cells
in treated cells. The values were
converted to the percentage of ap-
optotic cells. The mean values were
obtained from the three indepen-
dent experiments.
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tary Figure 3A and B). In terms of the affinity of ATP to
EGFR, EGFR with the L858R point mutation has little
affinity and EGFR with the deletion of exon 19 in the EGFR
gene has higher ATP affinity than the wild type.31,32 Yun et
al.33 reported that the affinity of ATP to EGFR with the
L858R mutation was about 20-fold less of that with L858R
T790M mutation in NSCLC, and that the high affinity of ATP
to EGFR with the L858RT790M mutation contributes to
gefitinib resistance in NSCLC. In this study, measurement of
intracellular ATP levels revealed that FK866 markedly re-
duced the intracellular ATP level in H1975 cells (Figure 3).
Therefore, we speculated that this was the reason H1975 was
very sensitive to FK866 compared with LC2. Our results
suggested that the growth inhibition of a NAMPT inhibitor
probably depends on not only expression levels of NAMPT-
mRNA or protein but also affinity of intracellular ATP to
EGFR with mutations in NSCLC. Explanation for why LC2
cells were less sensitive to FK866 than H1975 cells, although
LC2 cells expressed low NAMPT-mRNA in comparison with
H1975, remains unclear. Nevertheless, our study indicates
that the NAMPT inhibitor may be effective predominantly on
NSCLC including H1975 cells that require a large amount of
intracellular-ATP. FK866 suppressed cell proliferation and
reduced intracellular ATP levels in H1975 cells, suggesting
that their EGFR signaling was attenuated by addition of
FK866. WB revealed that FK866 suppressed phosphorylation
of both EGFR and EGFR downstream proteins including Akt,
ERK1/2, and MEK1/2 (Figure 4A–C). It has been reported
that NAMPT activated ERK1/2 and PI3K/Akt signaling in
endothelial cells and prostate cancer cells.13,20 Nevertheless,
the effect of NAMPT suppression on the cell signaling
pathway has not been completely understood. Our study
revealed that NAMPT attenuation inactivated EGFR proteins
in lung cancer cells. Although these findings did not fully
explain the mechanism of NAMPT inhibition in NSCLC, our
results suggested that FK866 reduced intracellular ATP levels
and consequently dephosphorylated EGFR protein.
Next, we studied the mechanism of tumor suppression
using flow cytometry. The flow cytometry assays showed that
FK866 induced apoptosis in H1975 cells, whereas gefitinib
did not (Figure 5A, B). Sos et al.34 demonstrated that either
EGFR or EGFR-downstream signal inhibitors, including ir-
reversible EGFR-TKIs, did not show antitumor activity in
EGFRT790M-mutated cells. In contrast, the inhibition of
EGFR and EGFR-downstream activities showed tumoricidal
effects on EGFRT790M-mutated cells. In this study, FK866
inactivated both EGFR and EGFR-downstream signals as
described above (Figure 4A–C). Our results support the
theory reported by Sos et al. As described above, we
selected H1975 cells and studied apoptotic effects of
FK866 in this study.
We used a tumor-bearing mouse model to confirm the
efficacy of FK866 in H1975 cells in vivo. The tumor xeno-
graft model showed that FK866 had antitumor activity in
H1975 cells (Figure 6A). In vivo antitumor activity of FK866
against H1975 was not satisfactory in comparison with in
vitro results. In our study, immunohistochemical analysis
demonstrated that both gefitinib and FK866 dephosphory-
lated ERK1/2 (Figure 6B). These results revealed that FK866
suppresses the EGFR signaling pathway in EGFRT790M-mu-
tated NSCLC even in the xenograft model.
Finally, we measured NAMPT-mRNA expression in
NSCLC and evaluated in vitro the effect of FK866 under the
normoxic condition. Previous studies reported that hypoxia
up-regulated NAMPT-mRNA expression in adipocytes as
well as cancer cells.35–37 In this study, we administered
FK866 at a dose of 10 mg/kg twice daily to NSCLC-bearing
mice because Drevs et al.14 showed that the same dose of
FK866 generated high antitumor activity in a renal cell
carcinoma in a tumor-bearing mouse model. A hypoxic
condition in the tumor-bearing mouse model is a possible
explanation for this low activity, or the dose of FK866 in this
study might be too low to inhibit H1975 tumors in the
xenograft model. In this study, the dose of FK866 and the
hypoxic condition could explain why the growth inhibition
was not prominent in the in vivo study. Drug delivery to the
tumor must be considered when FK866 is used to treat human
cancer. Again, a new drug delivery system might be a good
method to overcome the problem. In conclusion, our findings
FIGURE 6. FK866 suppresses in vivo growth of H1975 tu-
mors and inactivates ERK1/2 signals in the tumors. A, Nude
mice were transplanted with H1975 cells and treated with
12.5 mg/kg gefitinib or 10 mg/kg FK866 on days 14 to 26.
The graph shows tumor volumes measured. *p  0.05. B,
Immunohistochemistry shows the expression of p-ERK1/2
proteins in xenograft tumors (40). Compared with the
control (upper) and gefitinib (lower) groups, FK866 sup-
pressed the expression of p-ERK1/2 in the tumor (middle).
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indicate that FK866 is useful for the treatment of EGFR-
gene-mutated NSCLC, including gefitinib-resistant NSCLC.
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